Corrections: Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis (The Lancet Infectious Diseases (2018) 18(8) (913–923), (S1473309918302974) (10.1016/S1473-3099(18)30297-4));Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis

The Lancet Infectious Diseases

Volumn 18, Issue 8, 2018, Pages 913-923

  Chan, Xin Hui S ^a,b,c   Win, Yan Naung ^a,d   Mawer, Laura J ^a,e   Tan, Jireh Y ^a   Brugada, Josep ^f   White, Nicholas J ^a,b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Defence Services Medical Research Centre Health and Disease Control Unit   (Myanmar)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERAKINE; D ARTEPP; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUO COTECXIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ANTIPROTOZOAL THERAPY; ARTICLE; CASE MANAGEMENT; DIRECTLY OBSERVED THERAPY; DRUG SAFETY; ELIMINATION HALF-LIFE; HEART VENTRICLE ARRHYTHMIA; HUMAN; IATROGENIC DISEASE; INFECTION PREVENTION; MALARIA; MALARIA FALCIPARUM; MASS DRUG ADMINISTRATION; META ANALYSIS; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM MALARIAE INFECTION; PLASMODIUM OVALE; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECOND TRIMESTER PREGNANCY; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; ADOLESCENT; ANIMAL; BAYES THEOREM; CAUSE OF DEATH; COHORT ANALYSIS; COMBINATION DRUG THERAPY; FEMALE; MORTALITY; MOZAMBIQUE; PROSPECTIVE STUDY;

ADOLESCENT; ANIMALS; ANTIMALARIALS; ARTEMISININS; BAYES THEOREM; CAUSE OF DEATH; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA; MOZAMBIQUE; PROSPECTIVE STUDIES; QUINOLINES;

EID: 85048096221     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30419-5     Document Type: Erratum

References (64)

1. WHO. World Malaria Report 2017. 2017, World Health Organization, Geneva.
2. WHO. World Malaria Report 2015. 2015, World Health Organization, Geneva.
3. Adjei, A, Narh-Bana, S, Amu, A, et al. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J, 15, 2016, 43.
4. Zani, B, Gathu, M, Donegan, S, Olliaro, PL, Sinclair, D, Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev, 1, 2014 CD010927.
5. Gutman, J, Kovacs, S, Dorsey, G, Stergachis, A, ter Kuile, FO, Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis 17 (2017), 184–193.
6. Hoglund, RM, Workman, L, Edstein, MD, et al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med, 14, 2017, e1002212.
7. Tripura, R, Peto, TJ, Nguon, C, et al. A controlled trial of mass drug administration to interrupt transmission of multi drug resistant falciparum malaria in Cambodian villages. Clin Infect Dis, 2018 published online March 7. DOI:10.1093/cid/ciy196.
8. Landier, J, Kajeechiwa, L, Thwin, MM, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of eastern Myanmar. Wellcome Open Res, 2, 2017, 81.
9. Lwin, KM, Imwong, M, Suangkanarat, P, et al. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar J, 14, 2015, 319.
10. Eisele, TP, Bennett, A, Silumbe, K, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. J Infect Dis 214 (2016), 1831–1839.
11. Tran, TH, Dolecek, C, Pham, PM, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363 (2004), 18–22.
12. ICH Harmonised Tripartite Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf, 2005. (Accessed 20 November 2016)
13. European Medicines Agency. Eurartesim 160/20mg tablets: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf, 2011. (Accessed 15 May 2017)
14. White, NJ, Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7 (2007), 549–558.
15. Roden, DM, Predicting drug-induced QT prolongation and torsades de pointes. J Physiol 594 (2016), 2459–2468.
16. Sarganas, G, Garbe, E, Klimpel, A, Hering, RC, Bronder, E, Haverkamp, W, Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace 16 (2014), 101–108.
17. Molokhia, M, Pathak, A, Lapeyre-Mestre, M, et al. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol 66 (2008), 386–395.
18. Darpo, B, Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl(Supplement K), 2001, K70–K80.
19. WHO. WHO Evidence Review Group on the Cardiotoxicity of Antimalarial Medicines. 2017, World Health Organization, Geneva.
20. Ashley, EA, Recht, J, White, NJ, Primaquine: the risks and the benefits. Malar J, 13, 2014, 418.
21. Council for International Organizations of Medical Sciences (CIOMS). Evidence synthesis and meta-analysis: report of CIOMS Working Group X. 2016, CIOMS, Geneva.
22. Ackerman, M, Atkins, DL, Triedman, JK, Sudden cardiac death in the young. Circulation 133 (2016), 1006–1026.
23. Bagnall, RD, Weintraub, RG, Ingles, J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med 374 (2016), 2441–2452.
24. Bonny, A, Tibazarwa, K, Mbouh, S, et al. Epidemiology of sudden cardiac death in Cameroon: the first population-based cohort survey in sub-Saharan Africa. Int J Epidemiol 46 (2017), 1230–1238.
25. Faillie, JL, Ferrer, P, Gouverneur, A, et al. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol 86 (2017), 168–175.
26. R Core Team. R: A language and environment for statistical computing. 2017, R Foundation for statistical computing, Vienna.
27. Stan Development Team. RStanArm: Bayesian applied regression modeling via Stan. http://mc-stan.org, 2016. (Accessed 5 June 2018)
28. Desai, M, Gutman, J, L'Lanziva, A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet 386 (2015), 2507–2519.
29. Kakuru, A, Jagannathan, P, Muhindo, MK, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med 374 (2016), 928–939.
30. Natureeba, P, Kakuru, A, Muhindo, M, et al. Intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria among HIV-infected pregnant women. J Infect Dis, 22, 2017, 22.
31. Adam, I, Tarning, J, Lindegardh, N, Mahgoub, H, McGready, R, Nosten, F, Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 87 (2012), 35–40.
32. Pregact Study Group, Pekyi, D, Ampromfi, AA, et al. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med 374 (2016), 913–927.
33. Rijken, MJ, McGready, R, Boel, ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg 78 (2008), 543–545.
34. Rijken, MJ, McGready, R, Phyo, AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 55 (2011), 5500–5506.
35. Poespoprodjo, JR, Fobia, W, Kenangalem, E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One, 9, 2014, e84976.
36. Baiden, R, Oduro, A, Halidou, T, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J, 14, 2015, 160.
37. Borrmann, S, Sasi, P, Mwai, L, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One, 6, 2011, e26005.
38. Dicko, A, Brown, JM, Diawara, H, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis 16 (2016), 674–684.
39. Kheng, S, Muth, S, Taylor, WR, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med, 13, 2015, 203.
40. Lon, C, Manning, JE, Vanachayangkul, P, et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One, 9, 2014, e93138.
41. Nelwan, EJ, Ekawati, LL, Tjahjono, B, et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med, 13, 2015, 294.
42. Spring, MD, Lin, JT, Manning, JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15 (2015), 683–691.
43. Sutanto, I, Tjahjono, B, Basri, H, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 57 (2013), 1128–1135.
44. Bigira, V, Kapisi, J, Clark, TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med, 11, 2014, e1001689.
45. Kamya, MR, Kapisi, J, Bigira, V, et al. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS 28 (2014), 2701–2709.
46. Moore, BR, Benjamin, JM, Salman, S, et al. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 58 (2014), 5784–5794.
47. Annerberg, A, Lwin, KM, Lindegardh, N, et al. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother 55 (2011), 3971–3976.
48. Lwin, KM, Phyo, AP, Tarning, J, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56 (2012), 1571–1577.
49. Okebe, J, Bousema, T, Affara, M, et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin-piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine 13 (2016), 348–355.
50. Smithuis, F, Kyaw, MK, Phe, O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10 (2010), 673–681.
51. Sutanto, I, Suprijanto, S, Kosasih, A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in south Sumatra, western Indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 56 (2013), 685–693.
52. Tun, KM, Jeeyapant, A, Imwong, M, et al. Parasite clearance rates in upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J, 15, 2016, 185.
53. Chu, CS, Bancone, G, Moore, KA, et al. Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med, 14, 2017, e1002224.
54. Lidia, K, Dwiprahasto, I, Kristin, E, Therapeutic effects of dihydroartemisinin piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang, east Nusa Tenggara, Indonesia. Int J Pharm Sci Rev Res 31 (2015), 247–251.
55. Pasaribu, AP, Chokejindachai, W, Sirivichayakul, C, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis 208 (2013), 1906–1913.
56. ICH Harmonised Tripartite Guideline E6(R1). Guideline for good clinical practice. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf, 1996. (Accessed 20 December 2017)
57. Poirot, E, Skarbinski, J, Sinclair, D, Kachur, SP, Slutsker, L, Hwang, J, Mass drug administration for malaria. Cochrane Database Syst Rev, 12, 2013 CD008846.
58. Coldiron, ME, Lasry, E, Bouhenia, M, et al. Intermittent preventive treatment for malaria among children in a refugee camp in northern Uganda: lessons learned. Malar J, 16, 2017, 218.
59. Chugh, SS, Reinier, K, Balaji, S, et al. Population-based analysis of sudden death in children: the Oregon Sudden Unexpected Death Study. Heart Rhythm 6 (2009), 1618–1622.
60. Bouchaud, O, Imbert, P, Touze, JE, Dodoo, AN, Danis, M, Legros, F, Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J, 8, 2009, 289.
61. Reuter, SE, Evans, AM, Shakib, S, et al. Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Clin Drug Investig 35 (2015), 559–567.
62. Sim, IK, Davis, TM, Ilett, KF, Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 49 (2005), 2407–2411.
63. WHO. Guidelines for the treatment of malaria. 3rd edn., 2015, World Health Organization, Geneva.
64. Pal, SN, Duncombe, C, Falzon, D, Olsson, S, WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf 36 (2013), 75–81.